Updates matching "Childhood Cancer Research"

The Senate has advanced the U.S. Food and Drug Administration’s (FDA) Reauthorization Act, which expands four separate user fee agreements on new drugs, generic drugs, medical devices, and biosimilars, and includes a provision to maximize the development of therapies for children with cancer.

The president’s proposed 2018 budget, would decrease the National Institutes of Health budget by 21 percent, decrease the National Cancer Institute budget by 25 percent, cut the Centers for Disease Control and Prevention’s chronic disease program by nearly 20 percent and reduce Medicaid funding by more than $600 billion.

More than 200 childhood cancer advocates will be on Capitol Hill on May 2 to ask Congress to support initiatives that would increase research and improve treatment, leading to better outcomes for children with cancer.

ACS CAN applauds the introduction of the Research to Accelerate Cures and Equity (RACE) for Children Act (H.R. 1231/S. 456) – bipartisan legislation that would expand drug research for children with cancer, leading to better outcomes for pediatric patients.

The Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act (H.R. 820 and S. 292) introduced yesterday in Congress would help improve survivorship, treatment and access to care for childhood cancer patients and expand research into childhood cancers and care.

On December 6, the U.S. House of Representatives approved the bipartisan Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which advances pediatric cancer research and increases transparency and expertise for pediatric cancer research at the National Institutes of Health (NIH).

A first of its kind joint report today from the American Cancer Society and Alliance for Childhood Cancer compiles the latest information related to pediatric cancer, including statistics and trends, a current list of drugs used to treat pediatric cancers, ongoing pediatric cancer clinical trials, and research funding levels.